Capmatinib Triggers Responses in NSCLC.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
16
11
2018
medline:
16
11
2018
entrez:
16
11
2018
Statut:
ppublish
Résumé
A phase II trial of the MET inhibitor capmatinib found that 72% of treatment-naïve patients responded to the drug, whereas the response rate for previously treated patients was 39.1%. The drug's side effects include peripheral edema, nausea, and vomiting.
Identifiants
pubmed: 30429129
pii: 2159-8290.CD-NB2018-148
doi: 10.1158/2159-8290.CD-NB2018-148
doi:
Types de publication
News
Langues
eng
Sous-ensembles de citation
IM
Pagination
OF6Informations de copyright
©2018 American Association for Cancer Research.